Last reviewed · How we verify
NCT06757725
Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity
NA trial testing colour doppler of the renal artery and measurement of resistive index in Systemic Lupus Erthematosus in 75 participants. Completed in 15 October 2023.
13 October 2023
Quick facts
| Lead sponsor | Kasr El Aini Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 75 |
| Start date | 3 September 2022 |
| Primary completion | 13 October 2023 |
| Estimated completion | 15 October 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- colour doppler of the renal artery and measurement of resistive index
Conditions studied
- Systemic Lupus Erthematosus — all drugs for Systemic Lupus Erthematosus →
- Lupus Glomerulonephritis — all drugs for Lupus Glomerulonephritis →
- Lupus Flare — all drugs for Lupus Flare →
Sponsor
Kasr El Aini Hospital
Who can join
18 and older, any sex, with Systemic Lupus Erthematosus or Lupus Glomerulonephritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study explores the role of the colour Doppler scanning of the renal arteries and its relation to the degree of disease affection in lupus nephritis
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06757725
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Lupus Erthematosus
Currently open trials in the same condition.
- NCT07348055 — A Study of GR1803 in Systemic Lupus Erythematosus · Phase 1, PHASE2 · recruiting
- NCT06828042 — Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases · Phase 1, PHASE2 · recruiting
- NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting
- NCT07136389 — Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus · Phase 1 · recruiting
- NCT06792799 — Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease · EARLY_PHASE1 · recruiting
Other Kasr El Aini Hospital trials
Trials by the same sponsor.
- NCT07438652 — Effect of Mediterranean vs Paleolithic Diet on RA Activity, Sarcopenia and QOL: 12-Week RCT · NA · recruiting
- NCT07488039 — Labroplasty in Cases of Anterior Shoulder Instability With Subcritical Glenoid Bone Loss · NA · recruiting
- NCT07274280 — Comparative Evaluation of Ambu AuraGain, LarySeal Pro and I-gel in Pediatric Airway Management for Day-Case Surgery Unde · NA · not yet recruiting
- NCT07348146 — Hand-Sewn vs. Stapled Anastomosis in SADI-S: Early Postoperative Complications. · NA · enrolling by invitation
- NCT07077265 — Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06757725 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kasr El Aini Hospital
- Last refreshed: 3 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06757725.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing